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Engineering Life:  Ethics and Biotechnology 
 
Fall Semester, 2005   
Wed., 3:10 - 6:00   
LA 307    
Office Hours: TTh, 2:30-4:00 
 University of Montana 
 Mark J. Hanson, Ph.D. 
 mark.hanson@mso.umt.edu 
 Office:  LA 152, X6844 
     
 
Course Description and Objectives:  This three-credit class examines the ethical issues 
raised in the major areas of biotechnology.  Emerging biotechnologies are giving us new 
powers to manipulate the very building blocks of life.  We can imagine revolutionary 
medical treatments as well as designing life to suit our needs and desires.  Tremendous 
potential exists for human benefit, but also for harm and exploitation.  This course will 
examine fundamental ethical questions raised by the powers of biotechnology itself, as 
well as a range of possible applications, such as gene therapy, germline modification, 
genetic enhancements, cloning, stem cells, and related issues.  The course will also 
consider agricultural, plant, and animal realms, as well biotech commercialization.  The 
purpose of the course is to: 
 
1. Provide students with a basic understanding of the fundamental philosophical and 
social issues raised by biotechnology 
2. Provide students with an understanding of the major moral issues raised by 
biotechnology 
3. Advance students’ skills in critical thinking and writing in ethics through the 
consideration of contemporary issues and cases 
 
Prerequisites:   none, although a lower-level ethics course is helpful 
 
Requirements 
1. Mid-term examination,  (30 percent of grade) 
2. Ethics analysis paper (20 percent of grade) 
3. Participation in class discussions (20 percent of grade) 
4. Final examination, Dec.  (30 percent of grade) 
 
• Examinations will likely be a combination of a choice among short answer questions 
and a longer essay and/or case analysis.  The final examination will not be 
comprehensive but may be longer than the mid-term.  Exams must be taken at 
scheduled times unless prior permission of the instructor is obtained, otherwise the 
exam receives a failing grade. 
• The required paper should identify and concisely analyze a moral issue in 
biotechnology, which need not be among those discussed in this course.  Students are 
encouraged to discuss topics and ideas with the instructor in advance.  Unless an 
extension is granted, late papers are immediately penalized one grade, and thereafter 
at a graduated rate, amounting to an additional letter grade per five days.  The paper is 
due November 23. 
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• Class participation is central to achieving the learning goals for this course.  
Participation involves attendance, participating actively with group discussions, and 
being well prepared for discussions. 
• Students taking the course with the C/NCR option are required to achieve at least the 
equivalent of a D- to pass. 
 
Required Reading (available at the UM Bookstore) 
• Richard Sherlock and John D. Morrey, eds., Ethical Issues in Biotechnology (New 
York: Rowman & Littlefield Publishers, Inc., 2002) 
• Aldous Huxley, Brave New World (pb).  Used copies may be available. 
• Other articles on electronic and paper reserve (password:  “bioethics”) 
 
 
Topics and Reading Assignments  
 
Introduction:  Ethics and Biotechnology 
 
Aug. 31   Course Introduction; Ethics Introduction 
Bonnie Steinbock et. al, “Moral Reasoning in the Medical 
Context,” in Ethical Issues in Modern Medicine, ed. Bonnie 
Steinbock, John D. Arras, and Alex John London (New 
York: McGraw Hill, 2003. (on reserve) 
     
Sept. 7    Considering Biotechnology 
    • Sherlock & Morrey, pp. 47-87 
• Mary Midgley, “Biotechnology and Monstrosity: Why 
We Should Pay Attention to the ‘Yuk’ Factor,” Hastings 
Center Report 30, no. 5 (2000): 7-15. (on reserve) 
 
Sept. 14   Brave New World?  
    Huxley, Brave New World 
 
Human Applications  
 
Sept. 21   Human Gene Transfer 
Sherlock & Morrey, pp. 461-501 
 
Sept. 28   Human Enhancement 
• Erik Parens, “The Goodness of Fragility: On the Prospect 
of Genetic Technologies Aimed at the Enhancement of 
Human Capacities,” Kennedy Institute of Ethics Journal 5, 
no. 2 (1995): 141-53. (on reserve) 
• Sara Goering, “The Ethics of Making the Body Beautiful: 
What Cosmetic Genetics Can Learn from Cosmetic 
Surgery,” in Genetic Prospects: Essays on Biotechnology, 
Ethics, and Public Policy, ed. Verna V. Gehring (New 
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York: Rowman & Littlefield Publishers, Inc., 2003), pp. 
111-22. (on reserve) 
 
Oct. 5    Human Genetic Testing and Screening 
• The Council on Ethical and Judicial Affairs of the 
American Medical Association, “Ethical Issues Related to 
Prenatal Genetic Testing” 
• Adrienne Asch, “Prenatal Diagnosis and Selective 
Abortion: A Challenge to Practice and Policy,” American 
Journal of Public Health 89, no. 11 (November 1999): 
1649-57. (on reserve) 
 
Oct. 12     Human Reproductive Cloning 
• Sherlock & Morrey, pp. 551-81 
• NBAC Executive Summary (on reserve) 
• Courtney Campbell, “Prophecy and Policy,” Hastings 
Center Report 27, no. 5 (1997): 15-17. (on reserve) 
 
Oct. 19   Stem Cell Research 
• NBAC Executive Summary (on reserve) 
• Gilbert Meilaender, “The Point of a Ban,” Hastings 
Center Report 31, no. 1 (Jan.-Feb. 2001): 9-16. (on reserve) 
 
 
Examination 
 
Oct. 26   Mid-term Examination 
 
     
Non-human Applications 
 
Nov. 2    Agricultural Biotechnology 
• Sherlock & Morrey, pp. 111-26; 161-89 
• Wendell Berry, “Twelve Paragraphs on Biotechnology,” 
in Citzenship Papers (Washington, D.C.:  Shoemaker & 
Hoard, 2003), pp. 53-56. 
 
Nov. 9    Food Biotechnology 
    Sherlock & Morrey, pp. 191-201; 231-46 
     
Nov. 16   Animal Biotechnology 
    Sherlock & Morrey, pp. 271-86; 309-23 
 
Nov. 23   Xenotransplantation 
    • Sherlock & Morrey, pp. 341-58 
    Paper Due 
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Commercializing Biotechnology 
 
Nov. 30   Commercializing Biotechnology 
 • Jack Wilson, “Patenting Organisms: Intellectual Property 
Law Meets Biology,” Who Owns Life? (Boston: MIT Press, 
2002). (on reserve) 
• Vandana Shiva, “Beyond Reductionism,” in Biopolitics: 
A Feminist and Ecological Reader on Biotechnology 
(Atlantic Highlands, N.J.: Zed Books Ltd., 1995), pp. 267-
84. (on reserve) 
 
Conclusion 
 
Dec. 7    Looking Ahead; Conclusion 
    Reading TBA 
 
Examination 
 
Dec. 15, 1:10-3:10  Final Examination 
